Shanghai Bio-Heart Biological Technology Co., Ltd. Class H

As of December 31, 2024, Shanghai Bio-Heart Biological Technology Co., Ltd. Class H carries a market capitalization of 399.20M, placing it among publicly traded companies globally. Its enterprise value stands at 213.99M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Shanghai Bio-Heart Biological Technology Co., Ltd. Class H's next confirmed earnings release is scheduled for March 26, 2027.

As of December 31, 2024, Shanghai Bio-Heart Biological Technology Co., Ltd. Class H has 243.42M shares outstanding.

These figures are as of December 31, 2024.

As of December 31, 2024, Shanghai Bio-Heart Biological Technology Co., Ltd. Class H maintains a current ratio of 15.22, meaning it holds 15.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended December 31, 2024.

As of the close on October 23, 2026, Shanghai Bio-Heart Biological Technology Co., Ltd. Class H's stock has declined approximately 85.15% over the past 52 weeks. The 50-day moving average sits at 1.71, while the 200-day moving average is 3.53.

As of December 31, 2024, Shanghai Bio-Heart Biological Technology Co., Ltd. Class H holds 215.38M in cash and equivalents against 8.81M in total debt, resulting in a net debt position of -215.38M. Total book value stands at 702.88M, with working capital of 297.32M providing operational flexibility.